Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET)

Matthew H. Kulke, MD1; Jonathan R. Strosberg, MD2; Lynn Huynh, MPH, MBA, DrPH3; Mei Sheng Duh, MPH, ScD3; Vaibhav Sahai, MD, MS4; Alfred W. Rademaker, PhD4; and Al B. Benson, MD4

1Dana-Farber Cancer Institute, Boston, MA, USA
2Moffitt Cancer Center and Research Institute, Department of GI Oncology, Tampa, FL, USA
3Analysis Group, Inc., Boston, MA, USA
4Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

Background: Octreotide-LAR is commonly used in patients for control of carcinoid syndrome (CS) and other symptoms of hormone hypersecretion. We performed a medical record review to examine reasons for Octreotide-LAR dose-escalation and clinical outcomes in patients who underwent Octreotide-LAR dose-escalation at three large neuroendocrine tumor referral centers.

Methods: Medical records were abstracted for NET patients with diagnosis of carcinoid or pancreatic endocrine, ≥18 years old, and who had received ≥1 dose of Octreotide-LAR (>30mg/4 weeks). Reasons for dose-escalation and reports of flushing and diarrhea were abstracted for each patient 3 months prior to and up to 12 months following the dose-escalation.

Results: Medical records from 239 NET patients who had undergone dose-escalation above the standard Octreotide-LAR dose of 30mg/4 weeks were evaluated from 2000-2012. Of the evaluated patients, 53% were male, mean (SD) age at first dose-escalation was 60 (11) years, and mean (SD) time from Octreotide-LAR initiation to first dose-escalation was 1.7 (3.7) years. The primary stated reasons for dose-escalation were carcinoid or hormonal syndrome (62%) or radiographic progression (14%). The most common dose changes at first dose-escalation were 40 mg/4 weeks (71%) or 60 mg/4 weeks (18%). Of 90 patients in whom flushing was reported prior to dose-escalation, 73 (81%) were reported to have experienced improvement/resolution of their symptoms following the dose-escalation. Of 107 patients who were reported to have experienced diarrhea before the first dose-escalation, 85 (79%) were reported to have experienced improvement/resolution post first dose-escalation. Similar results (resolution/improvement – 80% flushing and 77% diarrhea) were observed when patients were excluded who had received concurrent treatments (e.g., liver-directed therapy, interferon-α) within 30 days of first dose-escalation.

Conclusion: A goal of improved symptom control is a common reason for dose-escalation of Octreotide-LAR. This retrospective review of medical records suggests that dose-escalation may result in improved symptom control.

Funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA